Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$115.44

0.24 (0.21%)

05:18
04/23/19
04/23
05:18
04/23/19
05:18

Eli Lilly announces sale of legacy antibiotics brands, facility in China

Eli Lilly announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China that produces Ceclor, to Eddingpharm, a China-based specialty pharmaceutical company. Under the terms of the agreement, Lilly will receive a deposit of $75M, followed by a payment of $300M upon successful closing of the transaction. As part of the transaction, all employees at the Ceclor manufacturing facility and certain employees from shared functions will be offered the opportunity to remain at the facility and continue to work with Eddingpharm. Lilly will provide ongoing services to Eddingpharm for a period of time to ensure continuity of product supply and support the smooth transition of the facility.

  • 24

    Apr

  • 30

    Apr

  • 04

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

LLY Eli Lilly
$115.44

0.24 (0.21%)

04/11/19
GUGG
04/11/19
DOWNGRADE
GUGG
Neutral
Guggenheim sees limited upside for Eli Lilly, downgrades to Neutral
As previously reported, Guggenheim analyst Seamus Fernandez downgraded Eli Lilly (LLY) to Neutral from Buy, stating that while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. Though he still thinks Eli Lilly has "the best long-term growth profile in US Pharma," that growth is the broad consensus view, said Fernandez, who removed his price target on the stock but estimates the fair value to be in the range of $125-$135 per share.
04/11/19
04/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chipotle (CMG) downgraded to Hold from Buy at Jefferies with analyst Andrew Barish saying after rallying 65% in Q1, Chipotle's valuation is full and reflects improved visibility for "powerful" same-store-sales and margin drivers. 2. Eli Lilly (LLY) downgraded to Neutral from Buy at Guggenheim with analyst Seamus Fernandez saying while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly's overall immunology portfolio and competition from Novo Nordisk's (NVO) semaglutide franchise is more fully understood. 3. U.S. Steel (X) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners citing worse near-term U.S. market conditions than she anticipated. 4. Keurig Dr Pepper (KDP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying she sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. 5. Waste Management (WM) downgraded to Hold from Buy at Stifel with analyst Michael Hoffman saying he factors in incrementally weaker paper prices and the impact of wet weather. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
04/22/19
BMOC
04/22/19
NO CHANGE
Target $130
BMOC
Outperform
Eli Lilly price target lowered to $130 from $134 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Eli Lilly to $130, saying the stock has underperformed along with its peers, and the news around its Tanezumab announced last week was "obviously negative". The analyst is keeping his Outperform rating however and believes that risk-reward on Eli Lilly is still "attractive" based on his "higher forecasts for Trulicity, Taltz, and Jardiance", as well as expectations around "improved margins". Arfaei adds that the company's upcoming REWIND data at the American Diabetes Association summit could be the "next major catalyst" for Eli Lilly shares.

TODAY'S FREE FLY STORIES

LOW

Lowe's

$108.00

9.96 (10.16%)

07:16
08/22/19
08/22
07:16
08/22/19
07:16
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 20

    Nov

COO

Cooper Companies

$332.66

0.39 (0.12%)

, ESLOY

EssilorLuxottica

$0.00

(0.00%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Recommendations
Cooper Companies, EssilorLuxottica analyst commentary  »

Cooper Companies price…

COO

Cooper Companies

$332.66

0.39 (0.12%)

ESLOY

EssilorLuxottica

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 04

    Sep

CERN

Cerner

$71.77

0.44 (0.62%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Upgrade
Cerner rating change  »

Cerner upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

TGT

Target

$103.11

17.54 (20.50%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

SLM

Sallie Mae

$8.29

0.07 (0.85%)

07:11
08/22/19
08/22
07:11
08/22/19
07:11
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae added to US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ORBC

Orbcomm

$4.84

-0.055 (-1.12%)

07:10
08/22/19
08/22
07:10
08/22/19
07:10
Upgrade
Orbcomm rating change  »

Orbcomm upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSD

Clearside Biomedical

$1.27

0.09 (7.66%)

07:10
08/22/19
08/22
07:10
08/22/19
07:10
Hot Stocks
Clearside Biomedical plans to resubmit XIPERE NDA in 1Q20 »

Clearside Biomedical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

RCKT

Rocket Pharmaceuticals

$11.44

0.115 (1.02%)

07:09
08/22/19
08/22
07:09
08/22/19
07:09
Hot Stocks
Rocket Pharmaceuticals announces clearance to commence Phase 2 FANCOLEN-II trial »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

HIW

Highwoods Properties

$43.92

0.14 (0.32%)

07:09
08/22/19
08/22
07:09
08/22/19
07:09
Conference/Events
Highwoods Properties to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

MYGN

Myriad Genetics

$25.12

0.67 (2.74%)

07:08
08/22/19
08/22
07:08
08/22/19
07:08
Hot Stocks
Myriad 'applauds' USPSTF recommendation on BRCA-related cancer prevention »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 13

    Nov

KSHB

KushCo Holdings

$0.00

(0.00%)

07:08
08/22/19
08/22
07:08
08/22/19
07:08
Hot Stocks
KushCo Holdings secures $50M credit facility from Monroe Capital »

KushCo Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$17.39

0.3 (1.76%)

07:07
08/22/19
08/22
07:07
08/22/19
07:07
Hot Stocks
Breaking Hot Stocks news story on Retrophin »

Retrophin down 25% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRAX

Social Reality

$3.39

-0.06 (-1.74%)

07:06
08/22/19
08/22
07:06
08/22/19
07:06
Hot Stocks
Social Reality changing name to SRAX August 26th »

SRAX will formally change…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLHF

Standard Lithium

$0.00

(0.00%)

07:05
08/22/19
08/22
07:05
08/22/19
07:05
Hot Stocks
Standard Lithium completes fabrication of Phase 1, 2 of 'LiSTR' plant »

Standard Lithium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLY

Fly Leasing

$18.25

0.265 (1.47%)

07:04
08/22/19
08/22
07:04
08/22/19
07:04
Hot Stocks
Fly Leasing CEO says 'FLY continues to achieve record results' »

"FLY continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 03

    Sep

  • 05

    Sep

WDAY

Workday

$190.87

4.53 (2.43%)

, CRM

Salesforce

$147.40

1.85 (1.27%)

07:04
08/22/19
08/22
07:04
08/22/19
07:04
Initiation
Workday, Salesforce initiated  »

Workday initiated with a…

WDAY

Workday

$190.87

4.53 (2.43%)

CRM

Salesforce

$147.40

1.85 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 12

    Dec

  • 16

    Dec

CLSD

Clearside Biomedical

$1.27

0.09 (7.66%)

07:03
08/22/19
08/22
07:03
08/22/19
07:03
Hot Stocks
Breaking Hot Stocks news story on Clearside Biomedical »

Clearside Biomedical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

FLY

Fly Leasing

$18.25

0.265 (1.47%)

07:03
08/22/19
08/22
07:03
08/22/19
07:03
Hot Stocks
Breaking Hot Stocks news story on Fly Leasing »

Fly Leasing board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 03

    Sep

  • 05

    Sep

USNA

Usana

$67.47

0.43 (0.64%)

07:02
08/22/19
08/22
07:02
08/22/19
07:02
Initiation
Usana initiated  »

Usana initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FLY

Fly Leasing

$18.25

0.265 (1.47%)

07:02
08/22/19
08/22
07:02
08/22/19
07:02
Earnings
Fly Leasing reports Q2 adjusted EPS $1.92, consensus $1.43 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 03

    Sep

  • 05

    Sep

PTITF

Indosat

$0.00

(0.00%)

07:01
08/22/19
08/22
07:01
08/22/19
07:01
Downgrade
Indosat rating change  »

Indosat downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTY

Paylocity

$109.41

3.22 (3.03%)

07:01
08/22/19
08/22
07:01
08/22/19
07:01
Initiation
Paylocity initiated  »

Paylocity initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BERY

Berry Global

$39.94

0.57 (1.45%)

07:00
08/22/19
08/22
07:00
08/22/19
07:00
Initiation
Berry Global initiated  »

Berry Global reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$89.14

1.85 (2.12%)

06:59
08/22/19
08/22
06:59
08/22/19
06:59
Recommendations
Keysight Technologies analyst commentary  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TGT

Target

$103.11

17.54 (20.50%)

06:57
08/22/19
08/22
06:57
08/22/19
06:57
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.